BioVie (BIVI) Faces Securities Fraud Class Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial – Hagens Berman

BioVie (BIVI) Faces Securities Fraud Class Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial – Hagens Berman

SAN FRANCISCO, Feb. 16, 2024 (GLOBE NEWSWIRE) — Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now. Class Period: Aug. 5, 2021 – Nov. 29, 2023Lead Plaintiff Deadline: Mar. 19, 2024Visit: www.hbsslaw.com/investor-fraud/BIVI Contact An Attorney Now: BIVI@hbsslaw.com                     … Read more

Nexcella Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

Nexcella Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Vaishali Sanchorawala, MD, has joined the Nexcella Scientific Advisory Board.  Dr. Sanchorawala is internationally recognized for her pioneering work in development of novel agents to treat AL Amyloidosis, including the establishment of daratumumab as the standard … Read more

Consensus is a ChatGPT alternative with a scientific specialty

Consensus is a ChatGPT alternative with a scientific specialty

PARIS, April 1 — With the emergence of AI chatbots, it is now common to ask anything and everything to ChatGPT and the likes. That said, in some domains, especially science, these tools can be approximate and even misleading. However, one solution is aimed specifically at those working in scientific fields. More and more researchers … Read more